RxDoctor Payments Data

Christine Mitchell, APRN

Family · San Antonio, TXNPI 1295219145

Payments from drug & device makers

$11,590in general payments, 2019–2025

Across 449 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • OPKO Pharmaceuticals, LLC$1K
  • AstraZeneca$1K
  • Bayer$993
  • Amgen$942
  • Novo Nordisk$921
  • Travere Therapeutics, Inc.$649
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$11,589100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,590 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$3,996
Medicare patients
36
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$94,535
FarxigaDapagliflozin Propanediol111$92,955
RayaldeeCalcifediol30$54,679
MounjaroTirzepatide39$41,366
TrulicityDulaglutide32$32,587
Tolvaptan12$24,911
JardianceEmpagliflozin17$24,226
KerendiaFinerenone33$23,357
LinzessLinaclotide15$9,555
Irbesartan49$1,735
Febuxostat18$1,540
Nifedipine ErNifedipine40$1,361
Allopurinol128$1,100
Potassium Chloride23$932
Rosuvastatin Calcium70$914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$921$94,53574 claims
AstraZenecaFarxiga$1,098$92,955111 claims
Lilly USA, LLCMounjaro, Trulicity$416$73,95371 claims
OPKO Pharmaceuticals, LLCRayaldee$1,386$54,67930 claims
Boehringer IngelheimJardiance$41$24,22617 claims
BayerKerendia$993$23,35733 claims
AbbVieLinzess$47$9,55515 claims
ANI Pharmaceuticals, Inc.Valsartan$20$90028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →